Literature DB >> 34421149

MDMA to Treat PTSD in Adults.

Dustin Latimer1, Michael D Stocker1, Kia Sayers1, Jackson Green1, Adam M Kaye1, Alaa Abd-Elsayed1, Elyse M Cornett1, Alan D Kaye1, Giustino Varrassi1, Omar Viswanath1, Ivan Urits1.   

Abstract

Post-traumatic stress disorder (PTSD) has become one of the most common psychiatric diagnosis in the United States specifically within the veteran population. The current treatment options for this debilitating diagnosis include trauma-focused psychotherapies along with selective serotonin reuptake inhibitors (SSRI) and serotonin-norepinephrine reuptake inhibitors (SNRI).1 MDMA has recently been shown as a novel therapeutic agent with promisingly results in the treatment of PTSD. MDMA is a psychoactive compound traditionally categorized as a psychedelic amphetamine that deemed a Schedule I controlled substance in the 1980s. Prior to its status as a controlled substance, it was used by psychotherapists for an array of psychiatric issues. In more recent times, MDMA has resurfaced as a potential therapy for PTSD and the data produced from randomized, controlled trials back the desire for MDMA to be utilized as an effective pharmacologic therapy in conjunction with psychotherapy.2.
Copyright © 1964–2019 by MedWorks Media Inc, Los Angeles, CA All rights reserved. Printed in the United States.

Entities:  

Keywords:  MAPS; MDMA; PTSD; post traumatic stress disorder; psychotherapy

Mesh:

Substances:

Year:  2021        PMID: 34421149      PMCID: PMC8374929     

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  83 in total

1.  Pharmacology of MDMA in humans.

Authors:  M Farré; P N Roset; C H Lopez; M Mas; J Ortuño; E Menoyo; N Pizarro; J Segura; J Cami
Journal:  Ann N Y Acad Sci       Date:  2000-09       Impact factor: 5.691

2.  A comparative study of QT prolongation with serotonin reuptake inhibitors.

Authors:  Ana Ojero-Senard; Justine Benevent; Emmanuelle Bondon-Guitton; Geneviève Durrieu; Leila Chebane; Melanie Araujo; Francois Montastruc; Jean-Louis Montastruc
Journal:  Psychopharmacology (Berl)       Date:  2017-08-03       Impact factor: 4.530

3.  Cerebral oedema after ingestion of MDMA ("ecstasy") and unrestricted intake of water.

Authors:  S M Matthai; D C Davidson; J A Sills; D Alexandrou
Journal:  BMJ       Date:  1996-05-25

4.  Neurochemical profiles of some novel psychoactive substances.

Authors:  Les Iversen; Simon Gibbons; Ric Treble; Vincent Setola; Xi-Ping Huang; Bryan L Roth
Journal:  Eur J Pharmacol       Date:  2012-12-21       Impact factor: 4.432

Review 5.  The background and chemistry of MDMA.

Authors:  A T Shulgin
Journal:  J Psychoactive Drugs       Date:  1986 Oct-Dec

Review 6.  The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs.

Authors:  H Kalant
Journal:  CMAJ       Date:  2001-10-02       Impact factor: 8.262

7.  Drug discrimination studies with MDMA and amphetamine.

Authors:  R Oberlender; D E Nichols
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

8.  The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study.

Authors:  Michael C Mithoefer; Mark T Wagner; Ann T Mithoefer; Lisa Jerome; Rick Doblin
Journal:  J Psychopharmacol       Date:  2010-07-19       Impact factor: 4.153

9.  The Effects of Stress Exposure on Prefrontal Cortex: Translating Basic Research into Successful Treatments for Post-Traumatic Stress Disorder.

Authors:  Amy F T Arnsten; Murray A Raskind; Fletcher B Taylor; Daniel F Connor
Journal:  Neurobiol Stress       Date:  2015-01-01

10.  3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial.

Authors:  Marcela Ot'alora G; Jim Grigsby; Bruce Poulter; Joseph W Van Derveer; Sara Gael Giron; Lisa Jerome; Allison A Feduccia; Scott Hamilton; Berra Yazar-Klosinski; Amy Emerson; Michael C Mithoefer; Rick Doblin
Journal:  J Psychopharmacol       Date:  2018-10-29       Impact factor: 4.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.